Wellington Management Group
IPHA

Wellington Management Group’s Innate Pharma IPHA Stock Holding History

Wellington Management Group’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,334,652
Closed -$5.46M – 2138
2020
Q4 		$5.46M Sell
1,334,652
-21,945
-2% -$97.8K ﹤0.01% 1309
2020
Q3 		$5.39M Buy
1,356,597
+5,059
+0.4% +$28.7K ﹤0.01% 1251
2020
Q2 		$9.87M Buy
1,351,538
+17,428
+1% +$117K ﹤0.01% 1072
2020
Q1 		$8.91M Sell
1,334,110
-19,663
-1% -$133K ﹤0.01% 1064
2019
Q4 		$8.71M Buy
+1,353,773
New +$8.32M ﹤0.01% 1201

Other funds holding IPHA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Wellington Management Group's IPHA Position: Q1 2021 in Review

Wellington Management Group sold out of Innate Pharma (IPHA) in Q1 2021, closing a stake of 1,334,652 shares — an estimated $5.46M sold.

Wellington Management Group first reported a position in IPHA in Q4 2019 and held it in 5 quarters. The position peaked at $9.87M in Q2 2020. 7 funds tracked by Wall St. Rank hold IPHA as of Q1 2021.

  • Wellington Management Group reported no remaining Innate Pharma position as of Q1 2021 after selling out during the quarter.
  • Wellington Management Group sold 1,334,652 Innate Pharma shares in Q1 2021, an estimated $5.46M.
  • Wellington Management Group first reported a position in Innate Pharma in Q4 2019 and held it in 5 quarters.
  • Wellington Management Group's Innate Pharma position peaked at $9.87M in Q2 2020.
  • 7 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2021.

Based on Wellington Management Group's 13F filing for Q1 2021, filed 17 May 2021.